BRAF: which options do we have for these patients in second line?

2 / 22

BRAF MUTANT CANCER: PARTICULARITIES
• Predominant mutation: V600E (70-90%)
• BRAF V600E mutations are activating with an increased
kinase activity and oncogenic transformation
• Other activating mutations:
• BRAF V600K 7%-19% (in melanoma)
• Other: BRAF V600D (0.1%), V600R (1%), V600M
(0.3%), L597 substitutions (0.5%), and K601E
(0.7%).
• Inactivating or "low-activity MT typically involve
substitutions at codon 594.
• Other BRAF aberrations include amplification and
fusions.
Turski et al. Mol Cancer Therap 2016